Moleculin Biotech, Inc. (NASDAQ:MBRX) Short Interest Up 108.8% in January

Moleculin Biotech, Inc. (NASDAQ:MBRX) saw a large increase in short interest in the month of January. As of January 15th, there was short interest totaling 358,088 shares, an increase of 108.8% from the December 31st total of 171,538 shares. Based on an average daily volume of 156,481 shares, the short-interest ratio is presently 2.3 days. Approximately 17.9% of the company’s shares are sold short. Approximately 17.9% of the company’s shares are sold short. Based on an average daily volume of 156,481 shares, the short-interest ratio is presently 2.3 days.

Moleculin Biotech Stock Performance

NASDAQ:MBRX traded down $0.04 during mid-day trading on Friday, hitting $4.24. 17,512 shares of the company’s stock traded hands, compared to its average volume of 137,292. The company has a fifty day moving average of $5.07 and a 200 day moving average of $10.28. Moleculin Biotech has a twelve month low of $3.13 and a twelve month high of $91.25. The company has a market capitalization of $8.63 million, a P/E ratio of -0.13 and a beta of 1.62.

Moleculin Biotech (NASDAQ:MBRX) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.07. On average, research analysts expect that Moleculin Biotech will post -7.98 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Wall Street Zen lowered Moleculin Biotech to a “strong sell” rating in a research report on Friday, October 3rd. HC Wainwright reaffirmed a “buy” rating and issued a $22.00 price target (up previously from $4.00) on shares of Moleculin Biotech in a research note on Thursday, December 11th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Moleculin Biotech in a report on Thursday, January 22nd. Finally, Roth Mkm restated a “buy” rating on shares of Moleculin Biotech in a report on Monday, December 15th. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Moleculin Biotech presently has a consensus rating of “Moderate Buy” and an average price target of $61.00.

About Moleculin Biotech

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.

The company’s pipeline includes multiple product candidates at various stages of development.